SE9503495L - Nytt protein - Google Patents

Nytt protein

Info

Publication number
SE9503495L
SE9503495L SE9503495A SE9503495A SE9503495L SE 9503495 L SE9503495 L SE 9503495L SE 9503495 A SE9503495 A SE 9503495A SE 9503495 A SE9503495 A SE 9503495A SE 9503495 L SE9503495 L SE 9503495L
Authority
SE
Sweden
Prior art keywords
gly
asp
protein
ser
trp
Prior art date
Application number
SE9503495A
Other languages
English (en)
Other versions
SE9503495D0 (sv
Inventor
Per Aakesson
Lars Bjoerck
Original Assignee
Actinova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinova Ltd filed Critical Actinova Ltd
Priority to SE9503495A priority Critical patent/SE9503495L/sv
Publication of SE9503495D0 publication Critical patent/SE9503495D0/sv
Priority to PCT/SE1996/001238 priority patent/WO1997013786A1/en
Priority to US09/051,380 priority patent/US6576741B1/en
Priority to DE69634206T priority patent/DE69634206D1/de
Priority to EP96933703A priority patent/EP0862580B1/en
Priority to AU72332/96A priority patent/AU7233296A/en
Publication of SE9503495L publication Critical patent/SE9503495L/sv
Priority to US10/374,535 priority patent/US7361750B2/en
Priority to US11/418,770 priority patent/US7588762B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9503495A 1995-10-09 1995-10-09 Nytt protein SE9503495L (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein
PCT/SE1996/001238 WO1997013786A1 (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein sic
US09/051,380 US6576741B1 (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein SIC
DE69634206T DE69634206D1 (de) 1995-10-09 1996-10-02 Sic protein von streptococcus, ein inhibitor der komplement-vermittelten lyse
EP96933703A EP0862580B1 (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein sic
AU72332/96A AU7233296A (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein sic
US10/374,535 US7361750B2 (en) 1995-10-09 2003-02-26 Streptoccal inhibitor of complement-mediated lysis, protein SIC
US11/418,770 US7588762B2 (en) 1995-10-09 2006-05-05 Streptoccal inhibitor of complement-mediated lysis, protein SIC

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein

Publications (2)

Publication Number Publication Date
SE9503495D0 SE9503495D0 (sv) 1995-10-09
SE9503495L true SE9503495L (sv) 1997-04-10

Family

ID=20399743

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein

Country Status (6)

Country Link
US (3) US6576741B1 (sv)
EP (1) EP0862580B1 (sv)
AU (1) AU7233296A (sv)
DE (1) DE69634206D1 (sv)
SE (1) SE9503495L (sv)
WO (1) WO1997013786A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203880A2 (hu) * 1999-12-23 2003-03-28 Vmax Limited Virulencia gének, proteinek és alkalmazásuk
AU2002249342A1 (en) * 2001-03-14 2002-09-24 Cambridge University Technical Services Limited Assays, methods and means for targeting streptococcal inhibitor of complement (sic)
FR2886312B1 (fr) * 2005-05-26 2012-12-14 Abag Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a streptococcus pyogenes
AU2007307375B2 (en) 2006-10-10 2013-11-28 Regenesance B.V. Complement inhibition for improved nerve regeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367890A1 (en) 1988-11-11 1990-05-16 HighTech Receptor AB Protein Arp, with immunoglobulin A binding activity, cloning and expression thereof
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
SE9002212D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Igg binding protein

Also Published As

Publication number Publication date
US7361750B2 (en) 2008-04-22
US20040010117A1 (en) 2004-01-15
WO1997013786A9 (en) 2008-09-04
US6576741B1 (en) 2003-06-10
EP0862580A1 (en) 1998-09-09
AU7233296A (en) 1997-04-30
DE69634206D1 (de) 2005-02-24
WO1997013786A1 (en) 1997-04-17
US7588762B2 (en) 2009-09-15
US20060205925A1 (en) 2006-09-14
SE9503495D0 (sv) 1995-10-09
EP0862580B1 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
Anders et al. Isolation and characterization of amyloid‐related serum protein SAA as a low molecular weight protein
Carlen et al. Composition of pellicles formed in vivo on tooth surfaces in different parts of the dentition, and in vitro on hydroxyapatite
Takagi et al. Amino acid sequence studies on the α chain of human fibrinogen. Location of four plasmin attack points and a covalent cross-linking site
Blombäck et al. Primary Structure of Human Fibrinogen and Fibrin: II. STRUCTURAL STUDIES ON NH2-TERMINAL PART OF γ CHAIN
MX9202724A (es) Composicion que comprende un vector recombinante del agente lelystad y vacuna que comprende la misma.
Spiegelberg et al. Structural studies of human γD myeloma protein
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
UY24130A1 (es) Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes.
Karlsson et al. A structural feature of human immunoglobulin light chains: two compact domains connected by a small switch region
Despont et al. Structural studies on a human IgAl myeloma protein with a carboxy-terminal deletion
SE9503495D0 (sv) New protein
Prahl et al. Carboxy-terminal structure of the α chain of human IgA [immunoglobulin A] myeloma proteins
CA2259413A1 (en) Methods for determining the presence of brain protein s-100
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
JPH02147954A (ja) ヒトの血清または血漿におけるオステオカルシンの決定法
Jaton et al. Amino acid sequence of the N-terminal sixty-nine residues of heavy chain derived from a homogeneous rabbit antibody
FI913714A (fi) Peptider med foer a 1-mikroglobulin karakteristiska antigeniska determinanter.
NO903681L (no) Monoklonale antistoffer mot aktiverte ras-proteiner med aminosyremutasjoner i posisjon 13 i proteinet.
Kelly et al. Immunological studies on the major haptenic peptides from performic acid oxidized ferredoxin from Clostridium pasteurianum
Clyne et al. Characterization of staphylococcal λ-lysin
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae
AU9629498A (en) Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
Carding et al. Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody
Boroff et al. Amino acid analysis of the isolated and purified components from crystalline toxin of Clostridium botulinum type A

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9503495-5